A lactate-responsive gene signature predicts the prognosis and immunotherapeutic response of patients with triple-negative breast cancer.
Kaixiang FengYoucheng ShaoJun LiXiaoqing GuanQin LiuMeishun HuMengfei ChuHui LiFangfang ChenZong-Bi YiJingwei ZhangPublished in: Cancer innovation (2024)
We identified an LRG signature in TNBC, which could be used to predict the prognosis of patients with TNBC and gauge their response to immunotherapy. Our findings may help guide the precision treatment of patients with TNBC.